PeterDBoasbergMD

PubMed

• 39 citations
  Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE‐Mutant Uterine Carcinosarcoma
  Munveer S. Bhangoo, Peter Boasberg, Pareen Mehta, Julia A. Elvin, Siraj M. Ali, Winnie Wu, Samuel J. Klempner> ;The Oncologist. 2018 May 1
• 37 citations
  Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab.
  Alessandra Chen, Nabilah Ali, Peter Boasberg, Allen S. Ho> ;Journal of Clinical Medicine. 2018 Jan 10
• 336 citations
  Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
  Paul C. Tumeh, Matthew D. Hellmann, Omid Hamid, Katy K. Tsai, Kimberly Loo, Matthew A. Gubens, Michael Rosenblum, Christina L. Harview, Janis M. Taube, Nathan Handley,...> ;Cancer Immunology Research. 2017 May 1
• 81 citations
  A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
  Shailender Bhatia, Anna C. Pavlick, Peter D. Boasberg, John A. Thompson, George Mulligan, Michael D. Pickard, Hélène M. Faessel, Bruce J. Dezube, Omid Hamid> ;Investigational New Drugs. 2016 Apr 8
• 8 citations
  BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer
  Shane Mesko, Katherine Rosenthal, Peter D. Boasberg, Omid Hamid> ;Journal of Clinical Oncology. 2015 Sep 1
• 29 citations
  Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
  Lynn E. Spitler, Peter D. Boasberg, Steven J. O'Day, Omid Hamid, Scott Cruickshank, Shane Mesko, Robert W. Weber> ;American Journal of Clinical Oncology. 2015 Feb 1
• 64 citations
  Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
  Patrick A. Ott, Omid Hamid, Anna C. Pavlick, Harriet M. Kluger, Kevin B. Kim, Peter D. Boasberg, Ronit Simantov, Elizabeth Crowley, Jennifer Green, Thomas Hawthorne, T...> ;Journal of Clinical Oncology. 2014 Nov 10
• 1406 citations
  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
  , , , , , , , , , , , , , , , , , , , , , , , > ;Lancet. 2014 Sep 20
• 179 citations
  Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
  Antoni Ribas, Rene Gonzalez, Anna C. Pavlick, Omid Hamid, Thomas F. Gajewski, Adil Daud, Lawrence E. Flaherty, Theodore F. Logan, Bartosz Chmielowski, Karl D. Lewis, D...> ;The Lancet. Oncology. 2014 Aug 1
• 10 citations
  Systemic treatment of metastatic melanoma: new approaches.
  Omid Hamid, Peter D. Boasberg, Katherine Rosenthal, Steven J. O'Day> ;Journal of Surgical Oncology. 2011 Sep 15
• Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma.
  Boasberg PD, Weber RW, Cruickshank S, Hamid O, O'Day S, Spitler LE> ;J. Clin. Oncol.. 2011-05-20
• 57 citations
  Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
  Peter D. Boasberg, Charles H. Redfern, Gregory A. Daniels, David Bodkin, Christopher R. Garrett, Alejandro D. Ricart> ;Cancer Chemotherapy and Pharmacology. 2011 Apr 24
• 60 citations
  Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
  Peter D. Boasberg, Omid Hamid, Steven J. O'Day> ;Seminars in Oncology. 2010 Oct 1
• 55 citations
  Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma
  Kazuo Koyanagi, Steven J. O'Day, Peter D. Boasberg, Michael B. Atkins, He-Jing Wang, Rene Gonzalez, Karl D. Lewis, John A. Thompson, Clay M. Anderson, Jose Lutzky, Tho...> ;Clinical Cancer Research. 2010 Apr 15
• 32 citations
  Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma
  Steven J. O'Day, Michael B. Atkins, Peter D. Boasberg, He-Jing Wang, John A. Thompson, Clay M. Anderson, Rene Gonzalez, Jose Lutzky, Thomas Amatruda, Evan M. Hersh, Je...> ;Journal of Clinical Oncology. 2009 Dec 20
• 14 citations
  Prognostic Factors in Metastatic Melanoma Patients Treated with Biochemotherapy and Maintenance Immunotherapy
  David R. Minor, Dan H. Moore, Christine Kim, Mohammed Kashani-Sabet, Suraj S. Venna, Wei Wang, Peter D. Boasberg, Steven J. O'Day> ;The Oncologist. 2009 Oct 1
• Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma.
  Boasberg P, Cruickshank S, Hamid O, O'Day S, Weber R, Spitler L> ;J. Clin. Oncol.. 2009-05-20
• Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
  Minor DR, Kashani-Sabet M, Moore D, Kim C, Venna SS, Wang W, Boasberg PD, O'Day S> ;J. Clin. Oncol.. 2009-05-20
• A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma.
  Hwu P, Sznol M, Pavlick A, Kluger H, Kim KB, Boasberg P, Sanders D, Simantov R, Crowley E, Hamid O> ;J. Clin. Oncol.. 2009-05-20
• A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma.
  Hwu P, Sznol M, Kluger H, Rink L, Kim KB, Papadopoulos NE, Sanders D, Boasberg P, Ooi CE, Hamid O> ;J. Clin. Oncol.. 2008-05-20
• Prophylatic cranial irradiation (PCI) in patients (Pts) with stage IV metastatic melanoma (MM) receiving concurrent biochemotherapy (cBCT) and maintenance biotherapy (...
  Boasberg P, Minor DR, Hamid O, Weber JS, Wollman R, Anderson CM, O'Day SJ> ;J. Clin. Oncol.. 2008-05-20
• 82 citations
  Enhanced Survival Associated with Vitiligo Expression during Maintenance Biotherapy for Metastatic Melanoma
  Peter D. Boasberg, Dave S.B. Hoon, Lawrence D Piro, Maureen Martin, Akhide Fujimoto, Timothy S Kristedja, Sandeep Bhachu, Xing Ye, Regina Deck, Steven J. O'Day> ;The Journal of Investigative Dermatology. 2006 Dec 1
• 30 citations
  Management of metastatic melanoma 2005.
  Steven J. O'Day, Peter D. Boasberg> ;Surgical Oncology Clinics of North America. 2006 Apr 1
• A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM).
  O'Day S, Atkins M, Weber J, Thompson J, Anderson C, Gonzalez R, Lutzky J, Amatruda T, Hersh E, Boasberg P> ;J. Clin. Oncol.. 2005-06-01
• 43 citations
  Impact of Gene Polymorphisms on Clinical Outcome for Stage IV Melanoma Patients Treated with Biochemotherapy: An Exploratory Study
  Dongxin Liu, Steven J. O'Day, Dongyun Yang, Peter D. Boasberg, Robert Milford, Tim S. Kristedja, Susan Groshen, Jeffrey S. Weber> ;Clinical Cancer Research. 2005 Feb 1
• Join now to see all